CARLOMAGNO, FRANCESCA
CARLOMAGNO, FRANCESCA
Istituto di Endocrinologia e Oncologia Sperimentale ''G. Salvatore'' - IEOS
Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B
1995 Santoro M; Carlomagno F; Romano A; Bottaro DP; Dathan NA; Grieco M; Fusco A; Vecchio G; Mataskova B; Kraus MH; Di Fiore PP
Association between DNA methylation profile and malignancy in follicular-patterned thyroid neoplasms
2019 Affinito, Ornella; Salerno, Paolo; D'Alessio, Alfonso; Cuomo, Mariella; Florio, Ermanno; Carlomagno, Francesca; Proietti, Agnese; Giannini, Riccardo; Basolo, Fulvio; Chiariotti, Lorenzo; Cocozza, Sergio; Santoro, Massimo
Attacking cancer with molecularly targeted agents Editorial overview
2013 Santoro, M; Carlomagno, F
BAY 43-9006 inhibition of oncogenic RET mutants.
2006 Carlomagno, F; Anaganti, S; Guida, T; Salvatore, G; Troncone, G; Wilhelm, Sm; Santoro, M
Bioisosteric discovery of npa101.3, a second-generation ret/vegfr2 inhibitor optimized for single-agent polypharmacology
2020 Moccia M.; Frett B.; Zhang L.; Lakkaniga N.R.; Briggs D.C.; Chauhan R.; Brescia A.; Federico G.; Yan W.; Santoro M.; Mcdonald N.Q.; Li H.Y.; Carlomagno F.
BRAF is a therapeutic target in aggressive thyroid carcinoma.
2006 Salvatore G; De Falco V; Salerno P; Nappi TC; Pepe S; Troncone G; Carlomagno F; Melillo RM; Wilhelm SM; Santoro M.
Central role of RET in thyroid cancer
2013 Santoro M.; Carlomagno F.
Clinical case seminar: in vivo and in vitro characterization of a novel germline RET mutation associated with low-penetrant nonaggressive familial medullary thyroid carcinoma.
2006 D'Aloiso L; Carlomagno F; Bisceglia M; Anaganti S; Ferretti E; Verrienti A; Arturi F; Scarpelli D; Russo D; Santoro M; Filetti S.
Cloning and molecular characterization of a novel gene strongly induced by the adenovirus E1A gene in rat thyroid cells
2003 Visconti R; Schepis F; Iuliano R; Pierantoni GM; Zhang L; Carlomagno F; Battaglia C; Martelli ML; Trapasso F; Santoro M; Fusco A
Constitutive and AP20187-induced Ret activation in photoreceptors does not protect from light-induced damage.
2007 Allocca, M; Di Vicino, U; Petrillo, M; Carlomagno, F; Domenici, L; Auricchio, A
D898_E901 RET Deletion Is Oncogenic, Responds to Selpercatinib, and Treatment Resistance Can Arise Via RET-Independent Mechanisms
2023 Porcelli, Tommaso; Moccia, Marialuisa; De Stefano, Maria Angela; Ambrosio, Raffaele; Capoluongo, Ettore; Santoro, Massimo; Hadoux, Julien; Schlumberger, Martin; Carlomagno, Francesca; Salvatore, Domenico
Different mutations of the RET gene cause different human tumoral diseases
1999 Santoro, M; Melillo, Rm; Carlomagno, F; Visconti, R; De Vita, G; Salvatore, G; Fusco, A; Vecchio, G
Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
2022 Zhang, Lingtian; Moccia, Marialuisa; Briggs, David C.; Bharate, Jaideep B.; Lakkaniga, Naga Rajiv; Knowles, Phillip; Yan, Wei; Tran, Phuc; Kharbanda, Anupreet; Wang, Xiuqi; Leung, Yuet-Kin; Frett, Brendan; Santoro, Massimo; Mcdonald, Neil Q.; Carlomagno, Francesca; Li, Hong-yu
Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation
2021 Yan, Wei; Zhang, Lingtian; Lv, Fengping; Moccia, Marialuisa; Carlomagno, Francesca; Landry, Christophe; Santoro, Massimo; Gosselet, Fabien; Frett, Brendan; Li, Hong-yu
Dysfunction of the RET receptor in human cancer.
2004 Santoro, M; Carlomagno, F; Melillo, Rm; Fusco, A
Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2).
2003 Carlomagno F. ; Vitagliano D. ; Guida T. ; Basolo F. ; Castellone M.D. ; Melillo R.M. ; Fusco A. ; Santoro M.
Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology
2015 Frett, Brendan; Carlomagno, Francesca; Moccia Maria, Luisa; Brescia, Annalisa; Federico, Giorgia; DE FALCO, Valentina; Admire, Brittany; Chen, Zhongzhu; Qi, Wenqing; Santoro, Massimo; Li, Hongyu
Functional characterization of a novel FGFR1OP-RET rearrangement in hematopoietic malignancies
2014 Bossi D.; Carlomagno F.; Pallavicini I.; Pruneri G.; Trubia M.; Raviele P.R.; Marinelli A.; Anaganti S.; Cox M.C.; Viale G.; Santoro M.; Di Fiore P.P.; Minucci S.
Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas.
2004 Castellone MD; Guarino V; De Falco V; Carlomagno F; Basolo F; Faviana P; Kruhoffer M; Orntoft T; Russell JP; Rothstein JL; Fusco A; Santoro M; Melillo RM.
Genetic alterations in differentiated thyroid cancer: what can be expected for gene expression profiling of thyroid carcinomas
2003 Santoro, M; Melillo, Rm; Carlomagno, F; Castellone, Md; Vitagliano, D; Guida, T; Vecchio, G; Fusco, A
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B | 1-gen-1995 | Santoro M; Carlomagno F; Romano A; Bottaro DP; Dathan NA; Grieco M; Fusco A; Vecchio G; Mataskova B; Kraus MH; Di Fiore PP | |
| Association between DNA methylation profile and malignancy in follicular-patterned thyroid neoplasms | 1-gen-2019 | Affinito, Ornella; Salerno, Paolo; D'Alessio, Alfonso; Cuomo, Mariella; Florio, Ermanno; Carlomagno, Francesca; Proietti, Agnese; Giannini, Riccardo; Basolo, Fulvio; Chiariotti, Lorenzo; Cocozza, Sergio; Santoro, Massimo | |
| Attacking cancer with molecularly targeted agents Editorial overview | 1-gen-2013 | Santoro, M; Carlomagno, F | |
| BAY 43-9006 inhibition of oncogenic RET mutants. | 1-gen-2006 | Carlomagno, F; Anaganti, S; Guida, T; Salvatore, G; Troncone, G; Wilhelm, Sm; Santoro, M | |
| Bioisosteric discovery of npa101.3, a second-generation ret/vegfr2 inhibitor optimized for single-agent polypharmacology | 1-gen-2020 | Moccia M.; Frett B.; Zhang L.; Lakkaniga N.R.; Briggs D.C.; Chauhan R.; Brescia A.; Federico G.; Yan W.; Santoro M.; Mcdonald N.Q.; Li H.Y.; Carlomagno F. | |
| BRAF is a therapeutic target in aggressive thyroid carcinoma. | 1-gen-2006 | Salvatore G; De Falco V; Salerno P; Nappi TC; Pepe S; Troncone G; Carlomagno F; Melillo RM; Wilhelm SM; Santoro M. | |
| Central role of RET in thyroid cancer | 1-gen-2013 | Santoro M.; Carlomagno F. | |
| Clinical case seminar: in vivo and in vitro characterization of a novel germline RET mutation associated with low-penetrant nonaggressive familial medullary thyroid carcinoma. | 1-gen-2006 | D'Aloiso L; Carlomagno F; Bisceglia M; Anaganti S; Ferretti E; Verrienti A; Arturi F; Scarpelli D; Russo D; Santoro M; Filetti S. | |
| Cloning and molecular characterization of a novel gene strongly induced by the adenovirus E1A gene in rat thyroid cells | 1-gen-2003 | Visconti R; Schepis F; Iuliano R; Pierantoni GM; Zhang L; Carlomagno F; Battaglia C; Martelli ML; Trapasso F; Santoro M; Fusco A | |
| Constitutive and AP20187-induced Ret activation in photoreceptors does not protect from light-induced damage. | 1-gen-2007 | Allocca, M; Di Vicino, U; Petrillo, M; Carlomagno, F; Domenici, L; Auricchio, A | |
| D898_E901 RET Deletion Is Oncogenic, Responds to Selpercatinib, and Treatment Resistance Can Arise Via RET-Independent Mechanisms | 1-gen-2023 | Porcelli, Tommaso; Moccia, Marialuisa; De Stefano, Maria Angela; Ambrosio, Raffaele; Capoluongo, Ettore; Santoro, Massimo; Hadoux, Julien; Schlumberger, Martin; Carlomagno, Francesca; Salvatore, Domenico | |
| Different mutations of the RET gene cause different human tumoral diseases | 1-gen-1999 | Santoro, M; Melillo, Rm; Carlomagno, F; Visconti, R; De Vita, G; Salvatore, G; Fusco, A; Vecchio, G | |
| Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose | 1-gen-2022 | Zhang, Lingtian; Moccia, Marialuisa; Briggs, David C.; Bharate, Jaideep B.; Lakkaniga, Naga Rajiv; Knowles, Phillip; Yan, Wei; Tran, Phuc; Kharbanda, Anupreet; Wang, Xiuqi; Leung, Yuet-Kin; Frett, Brendan; Santoro, Massimo; Mcdonald, Neil Q.; Carlomagno, Francesca; Li, Hong-yu | |
| Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation | 1-gen-2021 | Yan, Wei; Zhang, Lingtian; Lv, Fengping; Moccia, Marialuisa; Carlomagno, Francesca; Landry, Christophe; Santoro, Massimo; Gosselet, Fabien; Frett, Brendan; Li, Hong-yu | |
| Dysfunction of the RET receptor in human cancer. | 1-gen-2004 | Santoro, M; Carlomagno, F; Melillo, Rm; Fusco, A | |
| Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2). | 1-gen-2003 | Carlomagno F. ; Vitagliano D. ; Guida T. ; Basolo F. ; Castellone M.D. ; Melillo R.M. ; Fusco A. ; Santoro M. | |
| Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology | 1-gen-2015 | Frett, Brendan; Carlomagno, Francesca; Moccia Maria, Luisa; Brescia, Annalisa; Federico, Giorgia; DE FALCO, Valentina; Admire, Brittany; Chen, Zhongzhu; Qi, Wenqing; Santoro, Massimo; Li, Hongyu | |
| Functional characterization of a novel FGFR1OP-RET rearrangement in hematopoietic malignancies | 1-gen-2014 | Bossi D.; Carlomagno F.; Pallavicini I.; Pruneri G.; Trubia M.; Raviele P.R.; Marinelli A.; Anaganti S.; Cox M.C.; Viale G.; Santoro M.; Di Fiore P.P.; Minucci S. | |
| Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas. | 1-gen-2004 | Castellone MD; Guarino V; De Falco V; Carlomagno F; Basolo F; Faviana P; Kruhoffer M; Orntoft T; Russell JP; Rothstein JL; Fusco A; Santoro M; Melillo RM. | |
| Genetic alterations in differentiated thyroid cancer: what can be expected for gene expression profiling of thyroid carcinomas | 1-gen-2003 | Santoro, M; Melillo, Rm; Carlomagno, F; Castellone, Md; Vitagliano, D; Guida, T; Vecchio, G; Fusco, A |